cancer

FDA Questions Effectiveness of Breast Cancer Drug

Friday, August 13, 2010 by: Megan Rostollan
Tags: breast cancer, drugs, health news

eTrust Pro Certified

Most Viewed Articles
Popular on Facebook
The five biggest lies about Ebola being pushed by government and mass media
White House admits staging fake vaccination operation to gather DNA from the public
Why does the CDC own a patent on Ebola 'invention?'
Ultraviolet light robot kills Ebola in two minutes; why doesn't every hospital have one of these?
EXCLUSIVE: Natural News tests flu vaccine for heavy metals, finds 25,000 times higher mercury level than EPA limit for water
Irrefutable proof we are all being sprayed with poison: 571 tons of toxic lead 'chemtrailed' into America's skies every year
Truvia sweetener a powerful pesticide; scientists shocked as fruit flies die in less than a week from eating GMO-derived erythritol
Russia taking McDonald's to court, threatens countrywide shutdown
Oregon man serving prison sentence for collecting rainwater on his own property
The best way to help your body protect itself against Ebola (or any virus or bacteria)
Senator who attacked Doctor Oz over dietary supplements received over $146,000 in campaign contributions from Big Pharma mega-retailer and Monsanto
Global warming data FAKED by government to fit climate change fictions
Healthy 12-year-old girl dies shortly after receiving HPV vaccine
Ebola outbreak may already be uncontrollable; Monsanto invests in Ebola treatment drug company as pandemic spreads
HOAX confirmed: Michelle Obama 'GMOs for children' campaign a parody of modern agricultural politics
Ben & Jerry's switches to non-GMO, Fair Trade ice cream ingredients
W.H.O. contradicts CDC, admits Ebola can spread via coughing, sneezing and by touching contaminated surfaces
Elliot Rodger, like nearly all young killers, was taking psychiatric drugs (Xanax)
Delicious
(NaturalNews) The Food and Drug Administration went public with its doubts about the effectiveness of a relatively new breast cancer drug (1). This drug was approved in 2008 after a clinical trial showed that it slowed the progression of breast cancer tumors. Initially the drug appeared promising and it was approved for treatment of breast, lung, colon, kidney, and brain cancers. The drug was the top selling cancer treatment last year for the manufacturing company, with total sales of 5.9 billion dollars world-wide and approximately 1.2 billion of that revenue coming from its use in the treatment of breast cancer (2). Now follow-up studies are failing to show that the drug extends the lives of cancer patients and the FDA is considering withdrawing its prior recommendation of this particular drug for use in treating breast cancer.

The drug was put through an accelerated approval process back in 2008 and its continued use was contingent on later drug trials confirming its effectiveness in extending the lives of breast cancer patients. Now that this ability is in question the continued use of the drug for treating breast cancer is as well. FDA reviewers said that follow-up studies submitted to them by the pharmaceutical company failed to show that the drug extended life expectancy in breast cancer patients, saying that those studies "failed to confirm the magnitude of (progression-free survival) improvement" that was seen in earlier breast cancer trials.

Early trials showed that patients' progression-free survival rate increased by 5.5 months on the drug in question. In later studies these numbers ranged from one month to under three months, which is not considered clinically meaningful.

Additionally, patients taking the tumor-starving drug showed potentially serious side effects, which included high blood pressure, fatigue, and problems with white blood cell levels (3). Other risks include gastrointestinal perforations, blood clots, and bleeds, when the drug is combined with chemotherapy treatment; these are risks the FDA is not certain are worth the potential benefits.

The FDA asked a panel of outside experts to analyze the data on the drug, and the outcome is expected to heavily influence the FDA's final decision about the drug. It is not expected that this cancer treatment will be removed from the market entirely, but its use in treating advanced breast cancer may no longer be recommended.

References:

1.http://tinyurl.com/2dgu4uj
2.http://tinyurl.com/24x5mju
3.http://www.usatoday.com/news/health/2010-07-...


About the author

Megan Rostollan is a Certified Family Herbalist and works with her husband David, a private natural health and nutrition consultant (www.reforminghealth.com). She is also the author of a blog which can be found at NaturalHousewifery.com. Her areas of greatest interest include women's reproductive and prenatal health, as well as organic and green living and dietary and lifestyle changes.


Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support NaturalNews.com by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite NaturalNews.com with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Colloidal Silver

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...

GET SHOW DETAILS
+ a FREE GIFT

Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.